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ERBB2 is frequently amplified in breast tumours as part of a wide region of amplification on chromosome 17q21. This amplicon
contains many candidate genes for breast cancer susceptibility. We used a genetic association study design to determine if common
genetic variation (frequency X5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B,
STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk. Sixteen tagging
single-nucleotide polymorphisms (tSNPs) selected within blocks of linkage disequilibrium from the HapMap database, one HapMap
singleton SNP, and six additional SNPs randomly selected from dbSNP were genotyped using Taqman in a large study set of British
women (2275 cases, 2280 controls). We observed no association between any of the genotypes or associated haplotypes and
disease risk. In order to simulate unidentified SNPs, we performed the leave-one-out cross-validation procedure on the HapMap
data; over 90% of the common genetic variation was well represented by tagging polymorphisms. We are therefore likely to have
tagged any common variants present in our population. In summary, we found no association between common genetic variation in
the 17q21 ERBB2 amplicon and breast cancer risk in British women.
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Only a small proportion of the excess familial risk associated with
breast cancer is accounted for by known highly penetrant genes,
BRCA1 and BRCA2. The remainder is probably due to a
combination of weakly predisposing alleles including both
common and rare variants (Pharoah et al, 2002; Dite et al, 2003).
We have previously shown that common alleles in ERBB2 are not
involved in breast cancer susceptibility (Benusiglio et al, 2005).
However, ERBB2 is part of a wider region of chromosome 17q21
frequently amplified in breast cancer. This amplicon encompasses
many genes and it is conceivable that, as suggested by the
variability of response to anti-ERBB2 therapy in patients with
ERBB2 amplification, more than one gene in the amplicon could
contribute to breast cancer susceptibility, development and
progression (Willis et al, 2003).
Kauraniemi et al (2001, 2003) first carried out a systematic
survey of copy number and expression patterns in all genes within
the 17q21 locus on breast cancer cell lines and tumour samples;
they identified a 200-kilobase (kb) minimal common region of
amplification around ERBB2 containing the following genes:
neurogenic differentiation 2 (NEUROD2), protein phosphatase 1
regulatory subunit 1B (PPP1R1B), START domain containing 3
(STARD3), titin-cap (TCAP), phenylethanolamine-N-methyltrans-
ferase (PNMT), CAB2 (Per1-Like Domain Containing 1 [PERLD1]),
C17ORF37, growth factor receptor-bound protein 7 (GRB7) and
zinc-finger protein subfamily 1A 3 (ZNFN1A3).
Gene expression levels in cancer cells together with knowledge
about protein function can help in assessing which genes are
involved in oncogenesis (Futreal et al, 2004). For example,
STARD3, PNMT, CAB2, C17ORF37 and GRB7 show a significant
correlation between amplification status and expression level
(Kauraniemi et al, 2001, 2003; Willis et al, 2003; Orsetti et al, 2004),
and STARD3, PNMT, CAB2, GRB7 and ZNFN1A3 could all be
biologically relevant to breast cancer. STARD3 mediates intracel-
lular trafficking of cholesterol and can augment steroid hormone
synthesis (Strauss, III et al, 2003). Overexpression of PNMT results
in suppression of circulating leptin levels – a potent regulator of
body weight – in transgenic mice (Bottner et al, 2000; Harvey and
Ashford, 2003). CAB2 is a human homologue of the yeast COS16
gene required for the repair of DNA double-strand breaks (Nezu
et al, 2002) and GRB7 regulates cell migration through its
involvement in cell signalling pathways (Han et al, 2001). Finally,
ZNFN1A3 appears to function as a tumour suppressor since its
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(Rebollo and Schmitt, 2003).
Two neighbouring genes, peroxisome proliferator-activated
receptor binding protein (PPARBP) and CDC2-related protein
kinase 7 (CRK7), located about 50 kb upstream from NEUROD2 –
the first gene on the minimum region of amplification – are often,
although less consistently, co-amplified with ERBB2 (Kauraniemi
et al, 2001, 2003). Both are potentially implicated in cancer biology.
PPARBP, by its ability to function as an oestrogen receptor
coactivator, might play a role in mammary epithelial differentia-
tion (Zhu et al, 1999) while CRK7 could link transcription with the
splicing machinery (Ko et al, 2001).
The case–control study design is well suited to the identification
of small-effect genes that are likely to underlie common, complex
diseases such as breast cancer (Risch, 2000). Two approaches
have been proposed. The direct, hypothesis-driven approach is to
investigate single nucleotide polymorphisms (SNPs), which are
thought to have functional effects and thus influence directly
the traits under study (Tabor et al, 2002). The indirect, tagging
approach is to select a set of empirical tagging SNPs (tSNPs) that
best capture the common genetic variation within the gene. They
serve as markers to detect associations between a particular region
and diseases, whether or not the tSNPs themselves have a
functional effect (Gabriel et al, 2002). It is not necessary to
genotype all polymorphisms because the alleles of SNPs that are
physically close to each other tend to be correlated with each other:
they are in linkage disequilibrium (LD) (Pharoah et al, 2004). The
HapMap online database (http://www.hapmap.org) allows the
tagging approach to be applied readily to many genes or regions
(Gibbs et al, 2003). By March 2006, the database held the genotypes
of individuals with European, African-American, and Asian
ancestry for nearly four million SNPs.
We aimed to determine whether common genetic variation
(frequency 45%) in the ERBB2 amplicon is involved in breast
cancer susceptibility. We used HapMap data to identify tSNPs for
genotyping in a large breast cancer case–control study of white
British women. Data for five of the SNPs described in this report
have been previously published (Benusiglio et al, 2005), but are
also included here for completeness.
METHODS
Patients and controls
Cases were drawn from SEARCH, an ongoing population-based
study in which cases are ascertained through the East Anglian
Cancer Registry. All patients diagnosed with invasive breast cancer
below age 55 years since 1991 and still alive in 1996 (prevalent
cases; median age 48 years), together with all those diagnosed o70
years between 1996 and the present (incident cases; median age 52
years), were eligible to take part. All study participants completed
an epidemiological questionnaire and provided a blood sample for
DNA analysis. Sixty-seven percent of eligible breast cancer patients
returned a questionnaire and 64% provided a blood sample.
Controls were randomly selected from the Norfolk component of
EPIC (European Prospective Investigation of Cancer). EPIC is a
prospective study of diet and cancer being carried out in nine
European countries. The EPIC-Norfolk cohort comprises 25000
individuals resident in Norfolk, East Anglia, the same region from
which the cases have been recruited. Controls are not individually
matched to cases, but are broadly similar in age, being aged 42–81
years. The ethnic background of both cases and controls as
reported on the questionnaires is similar, with 498% being white.
All participants have given written consent and the study is
approved by the Eastern Region Multicentre Research Ethics
Committee.
A total of 4474 cases, of whom 27% were prevalent cases, and
4560 controls, were available for analysis. The samples have been
split into two sets in order to conserve DNA and reduce
genotyping costs. The first set (2275 cases, 2280 controls) is
genotyped for all SNPs. Any SNP that shows association in set 1 at
the Po0.1 level, can then be tested in the second set (2199 cases,
2280 controls). This staged approach substantially reduces
genotyping costs without significantly affecting statistical power
(see below). Cases with high yields of genomic DNA were selected
for set 1 from the first 3500 recruited, with set 2 comprising the
remainder of these plus the next 974 incident cases recruited. As
the prevalent cases were the first recruited, the proportion of
prevalent cases was somewhat higher in set 1 than set 2 (33 vs
20%). Median age at diagnosis was similar in both sets (51- and 52-
year-old, respectively). Median time from diagnosis to blood draw
was slightly longer for set 2 (15 months) than for set 1 (9 months).
There were no significant differences in the morphology,
histopathological grade or clinical stage of the cases by set or by
prevalent/incident status.
SNP identification and selection
The amplicon of interest is a 400-kb region, with PPARBP in
position 50 and ZNFN1A3 in position 30 (Figure 1). A 50-kb
segment located between CRK7 and NEUROD2 was excluded as
it contained no known gene, splitting the amplicon into a 150-kb
region including PPARBP and CRK7 (region A) and a 200-kb
region including NEUROD2, PPP1R1B, STARD3, TCAP, PNMT,
CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 (region B).
We used data on common SNPs from HapMap (European
samples, public release #15) to identify tSNPs. After exclusion of
one singleton SNP that was poorly linked with any other SNP (D0
o0.3), blocks of LD were defined on the basis of limited haplotype
diversity (common haplotypes must account for at least 90% of all
haplotypes) (Cardon and Abecasis, 2003). tSNPs were selected
within blocks using the tagSNPs program so that unmeasured
Excluded
Block 1 Block 2 Block 4 Block 3
PPARBP
CRK7
NEUROD2
PPP1R1B
STARD3
TCAP
PNMT
CAB2
ERBB2 GRB7
ZNFN1A3
C17ORF37
Figure 1 The 400-kb ERBB2 amplicon. It is split in two (regions A and B) by a 50-kb segment containing no known gene. Region A consists of one LD
block while region B consists of three blocks, blocks 2, 3 and 4.
Variation in the ERBB2 amplicon and breast cancer risk
PR Benusiglio et al
1690
British Journal of Cancer (2006) 95(12), 1689–1695 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sSNPs were tagged with a minimum rs
2 of 0.8 (Stram, 2004). The rs
2
coefficient measures LD between unmeasured SNPs and haplo-
types defined by the selected tSNPs. The five ERBB2 SNPs
previously genotyped (ERBB2-01 to -05) were forced as tSNPs
into the selection algorithm and SNPs surrounded by repetitive
DNA sequences were excluded (they could not be selected as
tSNPs). The average SNP density of the HapMap SNPs was 1 SNP/
5kb. In order to increase the SNP density and improve the tagging
properties of our SNP set, we also selected at the beginning of the
study additional random, validated polymorphisms from the
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP).
Genotyping
Genotyping was carried out using Taqman (Applied Biosystem,
Warrington, UK). Primers and probes were supplied directly by
Applied Biosystems, except those for ERBB2-04 and -05 that were
designed ‘in-house’ with the Primer Express Oligo Design Software
v2.0 (Applied Biosystems). Sequences are available on request.
Reactions were carried out at 54 or 601C in 384-well plates with
cases and controls plated together. Each plate included two
negative controls with no DNA and 12 samples duplicated on a
separate quality control plate. Plates were read on the ABI Prism
7900 using the Sequence Detection Software (Applied Biosystems).
Complete concordance between samples and their duplicates,
excluding undetermined genotypes, was required for the assay to
be validated. Failed genotypes were not repeated.
Statistical methods
For each SNP, deviation of genotype frequencies in controls from
Hardy–Weinberg (HW) equilibrium was assessed by a standard w
2
test (1 degree of freedom (df)). Genotype frequencies in cases and
controls were compared by a w
2 test for heterogeneity (2 df).
Genotype-specific risks were estimated as odds ratios (OR) using
standard cross-product ratio and confidence intervals were
calculated using the variance of the log (OR), which was estimated
by the standard Taylor expansion. A comparison of haplotype
frequencies between cases and controls was carried out using the
haplo.score routine implemented in S-plus (Schaid et al, 2002).
Haplotypes with an estimated frequency of o5% were pooled.
Haplo.score uses a likelihood that depends on estimated haplotype
frequencies to test the statistical association between haplotypes
and phenotype. It is based on score statistics, which provide both
global tests and haplotype-specific tests.
RESULTS
The HapMap release #15 included genotypes for 66 common SNPs
(26 in region A and 40 in region B). Region A consisted of only one
LD block, block 1 with 26 SNPs, whereas region B consisted of
three blocks, block 2 with 14 SNPs, block 3 with 11 SNPs and block
4 with 15 SNPs. One singleton SNP, ERBB2-04 (I655V), was
excluded from block 3, leaving 10 SNPs in block 3. Block 1
included PPARBP and CRK7, block 2 included NEUROD2,
PPP1R1B, STARD3 and TCAP, block 3 included CAB2 and ERBB2
and block 4 included C17ORF37, GRB7 and ZNFN1A3 (Figure 1).
Sixteen tSNPs were selected for genotyping: four in block 1,
three in block 2, five in block 3 and four in block 4 (Table 1).
ERBB2-04 - the HapMap singleton SNP – and six additional SNPs
randomly selected from dbSNP (one in block 2, four in block 3
and one in block 4) were also genotyped. None of the genotype
distributions in controls differed significantly from those expected
under HW equilibrium. There was no evidence that any of the
SNPs is associated with breast cancer, and none of the SNPs
exceeded the significance threshold for genotyping in the second
set of cases and controls (Table 2). The genotype-specific ORs were
all close to unity with confidence intervals including one (Figure 2).
The tSNPs generated five common haplotypes in block 1, three in
block 2, four in block 3 and four in block 4 (Table 3). The global
test of association was not significant for any of the four blocks
(P¼0.16, 0.58, 0.48 and 0.44 for blocks 1, 2, 3 and 4, respectively),
Table 1 SNPs selected for genotyping, the database they were selected from, the LD block to which they belong, their location within genes and their
frequencies in databases
SNP rs number Database Block Location Base change MAF
PPARBP-01 rs6503513 HapMap 1 START  1240 a4g 0.16
PPARBP-02 rs11655550 HapMap STOP +2808 t4c 0.24
CRK7-01 rs2303315 HapMap IVS10 +111 t4a 0.13
CRK7-02 rs4404103 HapMap IVS13 +88 a4g 0.12
NEUROD2-01 rs12453682 HapMap 2 STOP +5832 t4c 0.28
PPP1R1B-01 rs1874228 HapMap START  8372 g4a 0.24
PPP1R1B-02 rs879606 HapMap START  1797 g4a 0.13
STARD3-01 rs3817160 dbSNP IVS1 +331 c4g 0.45
CAB2-01 rs2952151 HapMap 3 START  560 c4t 0.28
CAB2-02 rs907087 dbSNP START  269 a4g 0.46
CAB2-03 rs1565920 dbSNP IVS5 +681 a4g 0.38
CAB2-04 rs907089 dbSNP IVS5 +2668 a4g 0.39
CAB2-05 rs1476278 HapMap IVS5 +5311 a4g 0.29
ERBB2-01 rs4252596 dbSNP START  657 c4a 0.07
ERBB2-02 rs2952155 HapMap IVS1 +5154 c4t 0.2
ERBB2-03 rs1810132 HapMap IVS4 +300 t4c 0.28
ERBB2-04 rs1801200 HapMap EX17 (I655V) a4g 0.33
ERBB2-05 rs1058808 HapMap EX27 (A1170P) g4c 0.29
C17ORF37-01 rs4252665 HapMap 4 START  26 c4t 0.06
GRB7-01 rs8192704 HapMap IVS2 +13 g4a 0.16
GRB7-02 rs11078921 dbSNP STOP +5330 c4a 0.26
ZNFN1A3-01 rs907091 HapMap START  361 c4t 0.47
ZNFN1A3-02 rs10445308 HapMap IVS2 +4027 c4t 0.48
Sixteen SNPs were HapMap tSNPs, one was a HapMap singleton (ERBB2-04) and six were randomly selected from the dbSNP database.
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individual haplotype frequencies.
DISCUSSION
We used a comprehensive SNP tagging approach using the
publicly available HapMap data, complemented by the random
selection of SNPs from dbSNP, to determine if common variation
in the ERBB2 amplicon is involved in breast cancer susceptibility.
A total of 23 SNPs in 4 LD blocks were genotyped; we saw no
association between any of the genotypes or associated haplotypes
and risk of breast cancer.
We could have failed to observe a true association because of
inadequate tagging, insufficient statistical power, or the effect of
confounders. The selection of tagging SNPs is most reliable where
the region of interest has been resequenced in a sample of
individuals sufficiently large to identify all common variants. Such
data were not available for this region, and it is possible that we
have not adequately tagged an unidentified, disease-predisposing
SNP. We estimated how well tSNPs would tag such unknown SNPs
by performing a leave-one-out cross validation procedure on the
HapMap data used for tSNP selection. Each of the 65 known SNPs
were dropped in turn and tSNPs selected from the remaining SNPs
within the block, thus simulating unidentified polymorphisms
(Ahmadi et al, 2005). The ability of the tSNPs to tag the dropped
SNP was then evaluated by calculating rs
2. The average rs
2 for all
dropped SNPs was 0.91 and 59 out of the 65 dropped SNPs (91%)
were tagged with an rs
240.75. This suggests that 91% of the
unknown variation was well tagged. Furthermore, it has been
shown that Phase 2 HapMap data provides a robust alternative to
complete re-sequencing data with minimal loss of power (De
Bakker et al, 2005). After we had completed the genotyping for this
study, data for phase 2 of the HapMap project were released. For
Table 2 Genotype frequencies, minor allele frequencies (MAF) and P-values for 23 SNPs genotyped in 2275 women with breast cancer and 2280
controls
SNP Series Number genotyped MAF Common homozygote Heterozygote Rare homozygote P-value
a
PPARBP-01 Cases 2190 0.20 1422 665 103 0.85
Controls 2274 1481 694 99
PPARBP-02 Cases 2181 0.19 1421 675 85 0.47
Controls 2273 1516 665 92
CRK7-01 Cases 2186 0.14 1658 499 29 0.36
Controls 2273 1685 551 37
CRK7-02 Cases 2193 0.10 1797 379 17 0.79
Controls 2275 1859 394 22
NEUROD2-01 Cases 2180 0.31 1020 941 219 0.4
Controls 2271 1090 937 244
PPP1R1B-01 Cases 2150 0.27 1152 833 165 0.95
Controls 2245 1210 860 175
PPP1R1B-02 Cases 2085 0.17 1435 585 65 0.94
Controls 2198 1520 607 71
STARD3-01 Cases 2158 0.22 1303 736 119 0.96
Controls 2266 1377 767 122
CAB2-01 Cases 2184 0.32 1042 923 219 0.71
Controls 2276 1064 969 243
CAB2-02 Cases 1923 0.31 930 801 192 0.84
Controls 2027 961 859 207
CAB2-03 Cases 2179 0.33 995 953 231 0.85
Controls 2274 1024 1014 236
CAB2-04 Cases 2185 0.34 961 969 255 0.78
Controls 2269 974 1025 270
CAB2-05 Cases 2038 0.35 901 890 247 0.58
Controls 2157 919 971 267
ERBB2-01 Cases 2023 0.13 1548 433 42 0.14
Controls 2189 1645 511 33
ERBB2-02 Cases 2040 0.26 1162 738 140 0.45
Controls 2205 1219 839 147
ERBB2-03 Cases 2050 0.32 969 861 220 0.69
Controls 2208 1022 956 230
ERBB2-04 Cases 1999 0.25 1134 752 113 0.67
Controls 2154 1229 791 134
ERBB2-05 Cases 2025 0.33 916 875 234 0.47
Controls 2180 960 982 238
C17ORF37-01 Cases 2169 0.03 1997 172 0 0.16
Controls 2259 2108 150 1
GRB7-01 Cases 2188 0.13 1676 474 38 0.36
Controls 2273 1703 533 37
GRB7-02 Cases 2171 0.34 954 969 248 0.85
Controls 2269 983 1032 254
ZNFN1A3-01 Cases 2088 0.49 561 1002 525 0.97
Controls 2214 600 1055 559
ZNFN1A3-02 Cases 2172 0.48 589 1086 497 0.99
Controls 2278 620 1140 518
aTest for heterogeneity of genotype frequencies between cases and controls (2 df).
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4.2kb. We used the programme TAGGER to test the performance
of our selected tSNPs on HapMap phase 2 (Paul de Bakker, http://
www.broad.mit.edu/mpg/tagger/). Mean pairwise r
2 (r
2
p) was 0.92
with 31 HapMap SNPs being tagged with r
2
p40.8 and a minimum
r
2
p of 0.21. For region B there were data on 57 SNPs (1 SNP/3.3kb).
Mean r
2
p was 0.91 with 53 HapMap SNPs being tagged with r
2
p40.8
and a minimum r
2
p of 0.12. These are conservative estimates since
additional SNPs with undetermined tagging properties were
randomly selected from dbSNP. Thus, the majority of common
genetic variation is likely to have been captured, but we cannot
exclude the possibility that an important common variant was
missed.
PNMT is thought to regulate leptin levels and could be relevant
to breast cancer biology via its effect on body weight (Harvey and
Ashford, 2003; Stattin et al, 2004). None of the HapMap SNPs were
in PNMT, raising questions regarding appropriate tagging of the
gene. Ahmadi et al (2005) studied tagging patterns across 55 genes,
including PNMT, that control the absorption, distribution,
metabolism and excretion of drugs; they were able to determine
that variation within PNMT was adequately tagged by rs1053651 in
TCAP and rs903502 in CAB2, two HapMap SNPs that were well
tagged by our set of tSNPs.
The statistical power of the study depends on the risk allele
frequency, the risks conferred and the genetic mode of action
(dominant, recessive, codominant). The staged approach substan-
tially reduces genotyping costs without significantly affecting
statistical power. For example, assuming that the causative SNP is
tagged with r
2
p¼0.8, a type I error rate of 0.0001 and genotyping
success rate of 0.95, the staged study has 86% power to detect a
dominant allele with a minor allele frequency (MAF) of 0.05 that
confers a relative risk of 1.5 or 87% power to detect a dominant
allele with a MAF of 0.25 that confers a relative risk of 1.3. Power to
detect recessive alleles is less – 53% for an allele with a MAF of 0.25
and a relative risk of 1.5 and 71% for an allele with a MAF of 0.5
and a relative risk of 1.3. Such high power is illustrated by the
narrow confidence intervals observed for odds ratios associated
with genotypes: heterozygote odds ratios higher than 1.28 were
excluded for all SNPs. Based on the upper confidence limits for all
the risk estimates we can exclude SNPs that explain more than
0.8% of the excess familial risk of breast cancer. The possibility of
variants with smaller effects on risk cannot be excluded. Similarly
the possibility that there are rare variants with modest, or even
large effect cannot be excluded.
Confounders are factors that are associated with both genotype
and phenotype. They may bias results towards false positives
and false negatives. In the context of breast cancer genetic
association studies, it is difficult to envisage a true confounder.
Most factors that are likely to be associated with both
genotype and breast cancer will be intermediate factors, not
confounders. The cases and controls used for these analyses were
not matched for age (though broadly similar). However, there was
no association of genotype with age in controls for any of the SNPs
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Figure 2 Genotype-specific risks for 23 SNPs genotyped in 2275 women with breast cancer and 2280 controls.
Table 3 Haplotype frequencies within LD blocks. ERBB2-04, a HapMap
singleton SNP, was excluded from block 3 for haplotype analyses as it is
poorly correlated with any other SNPs in the block
Block
Global test of
association Haplotype
Frequency in
controls (%) P-value
1 0.16 -a-t-t-a- 41 0.74
-a-c-t-a- 19 0.43
-g-t-t-a- 16 0.24
-a-t-a-a- 13 0.13
-a-t-t-g- 7 0.48
2 0.58 -t-g-g-c- 68 0.8
-c-a-a-g- 17 0.96
-c-a-g-c- 7 0.41
3 0.48 -c-a-a-a-a-c-c-t-g- 51 0.34
-t-g-g-g-g-c-t-c-c- 24 0.24
-c-a-a-a-a-a-c-t-g- 13 0.31
-t-g-g-g-g-c-c-c-c- 6 0.57
4 0.44 -c-g-c-t-c- 37 0.55
-c-g-a-c-t- 28 0.75
-c-g-c-c-t- 13 0.27
-c-a-c-t-c- 9 0.19
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unadjusted values.
Some authors have advocated the use of histopathologic or
demographic data that subclassify individuals in order to identify
homogeneous subsets for analysis (Rebbeck et al, 2004). In the
absence of any main effect or strong biological rationale, we
have not carried out subgroup analyses. The number of possible
post hoc, subgroup analyses is large and there is a strong
possibility that one or more tests will be statistically significant
simply by chance (Colhoun et al, 2003; Pharoah et al, 2005). Much
larger sample sizes would be required to obtain reliable results.
Nor did we test for SNP-SNP or SNP-environment interactions as
the number of such interactions is very large – there are over 2000
possible two- and three-way interactions between the 23 genotyped
common SNPs – and a clear strategy on how to best approach
interactions has yet to be defined (Ritchie et al, 2003; Hunter,
2005).
We found no evidence that common genetic variation in the
ERBB2 amplicon is associated with an altered risk of breast cancer.
The strategy of selecting candidate genes from regions that are
often amplified was not successful here, but we have only evaluated
a small proportion of the genome that is commonly somatically
altered in breast cancer. The search for common susceptibility
alleles for breast and the other common cancers using a candidate
gene approach has been notable for its lack of success. However,
there are many, possibly thousands, of candidate genes of which
only tens or hundreds have been comprehensively assessed for
susceptibility. Advances in our understanding of human genomic
architecture with rapid developments in high-throughput geno-
typing technology have made empirical, genome-wide association
(GWA) studies feasible. The results of the first GWA scans in
breast and colorectal cancer are expected in the near future. These
should provide evidence whether or not common susceptibility
variants exist. They may also provide an indication whether
candidate gene studies remain a valid approach and, if so, what the
likely candidates are.
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